{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:26Z","timestamp":1785132086681,"version":"3.55.0"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune thyroid diseases (AITDs), including Hashimoto\u2019s thyroiditis (HT) and Graves\u2019 disease (GD), affect approximately 2\u20135% of the global population. They are the most common organ-specific autoimmune disorders worldwide. Growing epidemiological and immunological evidence indicates that AITDs frequently coexist with immune-mediated dermatological diseases. These include atopic dermatitis (AD), psoriasis, alopecia areata (AA), vitiligo, and chronic spontaneous urticaria (CSU). Targeted immunotherapies have become central to the treatment of many immune-mediated skin diseases. Although these therapies are designed to act on specific immune pathways, they may also exert broader systemic immunomodulatory effects. However, thyroid function and thyroid autoantibodies are not routinely assessed in patients with immune-mediated dermatological conditions. This is also true for some patients with known or suspected AITDs. In this narrative review, we summarize the immunological overlap between cutaneous inflammation and autoimmune thyroid disease. We also discuss thyroid-related evidence for IL-4R\u03b1 inhibitors, IL-17 inhibitors, JAK inhibitors, IL-12\/23 inhibitors, and immune checkpoint inhibitors (ICIs). Current evidence suggests that ICIs have the strongest established association with thyroid dysfunction. In contrast, the thyroid-related effects of dupilumab and ustekinumab are supported mainly by rare case reports. IL-17 inhibitors and selective IL-23p19 inhibitors may theoretically attenuate thyroid inflammatory pathways. However, this possibility has not yet been confirmed in clinical studies. Based on the available evidence, we propose a risk-stratified approach to thyroid surveillance across targeted immunotherapies. Routine thyroid monitoring is most strongly supported for ICIs. For patients at increased thyroid risk, selective assessment of thyroid function and thyroid autoantibodies may also be considered during treatment with dupilumab or ustekinumab. For oral JAK inhibitors, monitoring may be particularly relevant before treatment, during therapy, and after discontinuation because of the potential for immune rebound. Prospective studies are needed to define which patient subgroups would benefit most from thyroid surveillance during targeted immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1890822","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:39:28Z","timestamp":1785130768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of dermatology targeted immunotherapies on autoimmune thyroid diseases: cytokine-network crosstalk and thyroid safety"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiahao","family":"Zhou","sequence":"first","affiliation":[{"name":"The First Clinical College, Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyang","family":"Han","sequence":"additional","affiliation":[{"name":"The First Clinical College, Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1729316","article-title":"Hashimoto's thyroiditis: from pathogenesis to clinical management","volume":"17","author":"Wang","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.3390\/ijms25136883","article-title":"The role of the immune system in the course of Hashimoto's thyroiditis: The current state of knowledge","volume":"25","author":"Wro\u0144ska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.794912","article-title":"Genetics, epigenetics, cellular immunology, and gut microbiota: Emerging links with Graves' disease","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15823","article-title":"Association of atopic dermatitis with thyroid diseases: A systematic review and meta-analysis","volume":"23","author":"Chen","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2026.18.1.145","article-title":"Lifetime atopic dermatitis is associated with risk of autoimmune thyroid disease: Evidence from a nationwide study","volume":"18","author":"Kim","year":"2026","journal-title":"Allergy Asthma Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jaad.2018.10.066","article-title":"Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14648","article-title":"Alopecia areata and overt thyroid diseases: A nationwide population-based study","volume":"45","author":"Han","year":"2018","journal-title":"J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15933","article-title":"Risk of autoimmune thyroid diseases in individuals with alopecia areata: A nationwide case-control study","volume":"24","author":"Wohl","year":"2026","journal-title":"J Dtsch Dermatol Ges"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.034","article-title":"Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea","volume":"76","author":"Bae","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00803","article-title":"The prevalence of thyroid disorders in patients with vitiligo: A systematic review and meta-analysis","volume":"9","author":"Yuan","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055538","article-title":"Prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/eje-17-0397","article-title":"The association of autoimmune thyroid disease (AITD) with psoriatic disease: a prospective cohort study, systematic review and meta-analysis","volume":"177","author":"Khan","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01761-2","article-title":"Chronic urticaria and thyroid autoimmunity: a meta-analysis of case-control studies","volume":"45","author":"Tienforti","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2017.9.4.373","article-title":"Increased risk of chronic spontaneous urticaria in patients with autoimmune thyroid diseases: A nationwide, population-based study","volume":"9","author":"Kim","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17945","article-title":"The association between melanoma and autoimmune diseases: A nationwide population-based study in the Republic of Korea","volume":"52","author":"Kim","year":"2025","journal-title":"J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02669-4","article-title":"Association between Hashimoto's thyroiditis and melanoma: a retrospective matched cohort study","volume":"315","author":"Gorman","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.03.001","article-title":"Incidence of melanoma is not elevated in patients with Graves' disease: A retrospective, matched-cohort study","volume":"11","author":"Deo","year":"2023","journal-title":"JAAD Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00290","article-title":"Vitiligo and autoimmune thyroid disorders","volume":"8","author":"Baldini","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.3390\/ijms24054894","article-title":"Conundrum for psoriasis and thyroid involvement","volume":"24","author":"Cira","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.09.012","article-title":"JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease","volume":"156","author":"Fujita","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8302-x","article-title":"Genetic and epigenetic mechanisms in thyroid autoimmunity","volume":"54","author":"Hasham","year":"2012","journal-title":"Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2018.33.2.175","article-title":"Genome-wide association studies of autoimmune thyroid diseases, thyroid function, and thyroid cancer","volume":"33","author":"Hwangbo","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.536","article-title":"A population-based study of chronic autoimmune hypothyroidism in Danish twins","volume":"85","author":"Brix","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa956","article-title":"Limited genetic overlap between overt Hashimoto's thyroiditis and Graves' disease in twins: A population-based study","volume":"106","author":"Skov","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/a-1972-5787","article-title":"Helper T cell 17 and regulatory T cell levels in peripheral blood of newly diagnosed patients with autoimmune thyroid disease: A meta-analysis","volume":"55","author":"Chen","year":"2023","journal-title":"Horm Metab Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102502","article-title":"PTPN22 through the regulation of Th17\/Treg balance acts as a potential target for the treatment of Graves' disease","volume":"90","author":"Cai","year":"2024","journal-title":"Tissue Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03490-9","article-title":"A role of NR4A2 in Graves' disease: regulation of Th17\/Treg","volume":"83","author":"Zhao","year":"2024","journal-title":"Endocrine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7499\/j.issn.1008-8830.2312017","article-title":"Expression of miR-142 and its relationship with Th17\/Treg imbalance in children with autoimmune thyroid disease","volume":"26","author":"Luo","year":"2024","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2024.2433628","article-title":"N6-methyladenosine modification of THBS1 induced by affluent WTAP promotes Graves' ophthalmopathy progression through glycolysis to affect Th17\/Treg balance","volume":"58","author":"Li","year":"2025","journal-title":"Autoimmunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12964-026-02915-y","article-title":"Metabolic reprogramming of Th17\/Treg imbalance in autoimmune thyroid diseases","volume":"24","author":"Zhou","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000311519","article-title":"Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment","volume":"18","author":"Pedro","year":"2011","journal-title":"Neuroimmunomodulation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.30699\/ijp.2025.2066164.3489","article-title":"Association of serum IL-35 and TGF-\u03b2 levels with the incidence, severity, and treatment response in Iraqi patients with Graves' disease","volume":"20","author":"Hussein","year":"2025","journal-title":"Iran J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature06878","article-title":"TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function","volume":"453","author":"Zhou","year":"2008","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008247107","article-title":"Human ROR\u03b3t+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors","volume":"107","author":"Valmori","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04034.x","article-title":"Association of the -31C\/T functional polymorphism in the interleukin-1beta gene with the intractability of Graves' disease and the proportion of T helper type 17 cells","volume":"158","author":"Hayashi","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2019.1600535","article-title":"Effect of IL-21 on the balance of Th17 cells\/Treg cells in the pathogenesis of Graves' disease","volume":"44","author":"Tan","year":"2019","journal-title":"Endocr Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"16880","DOI":"10.1038\/s41598-022-19556-z","article-title":"Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease","volume":"12","author":"Torimoto","year":"2022","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8431838","DOI":"10.1155\/2017\/8431838","article-title":"Increased circulating Th17 but decreased CD4(+)Foxp3(+) Treg and CD19(+)CD1d(hi)CD5(+) Breg subsets in new-onset Graves' disease","volume":"2017","author":"Qin","year":"2017","journal-title":"BioMed Res Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molimm.2022.02.004","article-title":"Absolute reduction in peripheral regulatory T cells in patients with Graves' disease and post-treatment recovery","volume":"144","author":"Liu","year":"2022","journal-title":"Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1719","article-title":"Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis","volume":"95","author":"Figueroa-Vega","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0220-6","article-title":"Helper T cell differentiation","volume":"16","author":"Saravia","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2023.07.002","article-title":"Th1 or Th2 cytokines are correlated with Tregs and T cell subsets and pregnancy outcomes in patients with autoimmune thyroid disease during early, middle, late pregnancy, and postpartum period","volume":"84","author":"Zhong","year":"2023","journal-title":"Hum Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej18-0396","article-title":"Upregulated tissue expression of T helper (Th) 17 pathogenic interleukin (IL)-23 and IL-1\u03b2 in Hashimoto's thyroiditis but not in Graves' disease","volume":"66","author":"Zake","year":"2019","journal-title":"Endocr J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0569-y","article-title":"The possible role of CD4+CD25(high)Foxp3+\/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with Hashimoto thyroiditis","volume":"50","author":"Xue","year":"2015","journal-title":"Endocrine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1159\/000452541","article-title":"Imbalance of Th17\/Treg in different subtypes of autoimmune thyroid diseases","volume":"40","author":"Li","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1098243","article-title":"The role behind the scenes of Tregs and Th17s in Hashimoto's thyroiditis: Toward a pivotal role of FOXP3 and BACH2","volume":"13","author":"Mazzieri","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2016.17.02.007","article-title":"Imbalances in T cell-related transcription factors among patients with Hashimoto's thyroiditis","volume":"17","author":"Safdari","year":"2017","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2024.10237","article-title":"The relationship of peripheral blood lncRNA-PVT1 and miR-146a levels with Th17\/Treg cytokines in patients with Hashimoto's thyroiditis and their clinical significance","volume":"24","author":"Li","year":"2024","journal-title":"Biomol BioMed"},{"key":"B52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/medsci14010061","article-title":"Hypoxia-inducible factor 1-\u03b1 in autoimmune diseases-insights from the paradigm of Hashimoto's thyroiditis: A narrative review","volume":"14","author":"Srb","year":"2026","journal-title":"Med Sci (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.001","article-title":"Immuno-metabolic control of the balance between Th17-polarized and regulatory T-cells during HIV infection","volume":"69","author":"Yero","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2586216","article-title":"Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases","volume":"57","author":"He","year":"2025","journal-title":"Ann Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.10.001","article-title":"Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients","volume":"149","author":"Li","year":"2013","journal-title":"Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1741116","article-title":"Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review","volume":"5","author":"Nakagawa","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf655","article-title":"Secukinumab in moderate-to-severe Graves orbitopathy: A randomized, double-blind, placebo-controlled, multicenter study","volume":"111","author":"Wolf","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.70078","article-title":"Targeting JAK-STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions","volume":"104","author":"Wu","year":"2026","journal-title":"Immunol Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669688","article-title":"JAK\/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders","volume":"16","author":"Djidjik","year":"2025","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-012-1754-1","article-title":"Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis","volume":"39","author":"Liang","year":"2012","journal-title":"Mol Biol Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/cells8030285","article-title":"IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis","volume":"8","author":"von Essen","year":"2019","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12016-020-08823-4","article-title":"IL-23\/IL-17 axis in inflammatory rheumatic diseases","volume":"60","author":"Li","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/imr.13230","article-title":"Engineering the IL-4\/IL-13 axis for targeted immune modulation","volume":"320","author":"Bernstein","year":"2023","journal-title":"Immunol Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.25301","article-title":"STAT6 and lung inflammation","volume":"2","author":"Walford","year":"2013","journal-title":"Jakstat"},{"key":"B70","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.3390\/ijms24076835","article-title":"Characterizing the interplay of lymphocytes in Graves' disease","volume":"24","author":"Hansen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.25259\/ijdvl_15_2023","article-title":"Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease","volume":"90","author":"Huang","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3011","article-title":"Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease","volume":"99","author":"Rapoport","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03756.x","article-title":"Distribution of immunoglobulin G subclasses of anti-thyroid peroxidase antibody in sera from patients with Hashimoto's thyroiditis with different thyroid functional status","volume":"154","author":"Xie","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0211","article-title":"A classification of Hashimoto's thyroiditis based on immunohistochemistry for IgG4 and IgG","volume":"24","author":"Zhang","year":"2014","journal-title":"Thyroid"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455050","article-title":"Biologic drugs induced vitiligo: case reports and review of literature","volume":"15","author":"Shao","year":"2024","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf483","article-title":"Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study","volume":"51","author":"Lauletta","year":"2026","journal-title":"Clin Exp Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2013type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89064","article-title":"Dupilumab-induced Graves' disease in an adult with chronic rhinosinusitis and nasal polyposis","volume":"17","author":"Gama","year":"2025","journal-title":"Cureus"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.415","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466372","article-title":"Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis","volume":"15","author":"Kamal","year":"2024","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907149","article-title":"Promising immunomodulatory effects of bacterial lysates in allergic diseases","volume":"13","author":"Kaczynska","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5164","article-title":"A novel human truncated IL12r\u03b21-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation","volume":"6","author":"Guo","year":"2015","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.3390\/ijms20143394","article-title":"Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases","volume":"20","author":"Bunte","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B87","first-page":"89","article-title":"Evaluation of CD4+CD161+CD196+ and CD4+IL-17+ Th17 cells in the peripheral blood of young patients with Hashimoto's thyroiditis and Graves' disease","volume":"18","author":"Bossowski","year":"2012","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cen.70114","article-title":"Hashimoto's thyroiditis beyond thyroid hormones: A systematic review of autoimmunity, inflammation, and multidimensional burden","volume":"105","author":"Alf\u00ec","year":"2026","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/147413","article-title":"Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer","volume":"2012","author":"Quatresooz","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5111","article-title":"Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy","volume":"27","author":"Khan","year":"2020","journal-title":"Curr Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688699","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1629879","article-title":"CTLA-4 and PD-1 combined blockade therapy for Malignant melanoma brain metastases: mechanisms, challenges, and prospects","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e240328","DOI":"10.1530\/etj-24-0328","article-title":"Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors","volume":"14","author":"Yamauchi","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1530\/ey.18.3.5","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1631321","article-title":"Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness","volume":"16","author":"Ameer","year":"2025","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.41250","article-title":"Is the increase in tumour markers and Hashimoto's thyroiditis an incidental event during dupilumab treatment? A case report","volume":"105","author":"Lin","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/82_2016_40","article-title":"Th1\/Th2 immune balance and other T helper subsets in IgG4-related disease","volume":"401","author":"Moriyama","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1530\/edm-20-0030","article-title":"Painless thyroiditis in a dupilumab-treated patient","volume":"2020","author":"Narantsatsral","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2300003","article-title":"Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab","volume":"7","author":"Campbell","year":"2023","journal-title":"Immunohorizons"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.008","article-title":"Psoriasis harbors multiple pathogenic type 17 T-cell subsets: selective modulation by risankizumab","volume":"155","author":"Kim","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/ptt.s165943","article-title":"Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date","volume":"8","author":"MaChado","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2802892","article-title":"A systematic review with meta-analysis of comparative efficacy and safety of risankizumab and ustekinumab for psoriasis treatment","volume":"2022","author":"Yu","year":"2022","journal-title":"J Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3084","article-title":"A case of interstitial lung disease and autoimmune thyroiditis associated with ustekinumab","volume":"99","author":"Lee","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s532526","article-title":"Brodalumab for moderate-to-severe psoriasis: a comprehensive review of efficacy, safety, and clinical positioning","volume":"19","author":"Babaei","year":"2025","journal-title":"Biologics"},{"key":"B117","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2012.702814","article-title":"Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases","volume":"45","author":"Yan","year":"2012","journal-title":"Autoimmunity"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191782","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100104","article-title":"Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases","volume":"4","author":"Akiyama","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.01.020","article-title":"Oral Janus kinase inhibitors for atopic dermatitis","volume":"130","author":"Mikhaylov","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1757562","article-title":"Targeting the JAK\/STAT pathway in atopic dermatitis","volume":"17","author":"Cui","year":"2026","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"BSR20200759","DOI":"10.1042\/bsr20200759","article-title":"Bioinformatics analysis of key genes and pathways in Hashimoto thyroiditis tissues","volume":"40","author":"Zheng","year":"2020","journal-title":"Biosci Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006867","article-title":"Human cytomegalovirus UL23 inhibits transcription of interferon-\u03b3 stimulated genes and blocks antiviral interferon-\u03b3 responses by interacting with human N-myc interactor protein","volume":"14","author":"Feng","year":"2018","journal-title":"PloS Pathog"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035020","article-title":"Pathological mechanism and targeted drugs of ulcerative colitis: a review","volume":"102","author":"Guo","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B131","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311706","article-title":"JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: a potential mechanism for major adverse cardiac events","volume":"20","author":"Gurevic","year":"2025","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.56.gp211","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34696","article-title":"A rare case of pembrolizumab-associated Graves' disease","volume":"15","author":"Alqaisi","year":"2023","journal-title":"Cureus"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B138","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.3390\/cancers13215277","article-title":"The continuum of thyroid disorders related to immune checkpoint inhibitors: still many pending queries","volume":"13","author":"Deligiorgi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system","volume":"27","author":"Lu","year":"2022","journal-title":"Oncologist"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581057","article-title":"Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12902-025-01986-1","article-title":"Risk factors and outcomes of thyroid immune-related adverse events following PD-1\/PD-L1 inhibitors treatment in a large tertiary Chinese center","volume":"25","author":"Gong","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B144","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12902-022-01190-5","article-title":"Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms","volume":"22","author":"de Filette","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des Devel Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:39:32Z","timestamp":1785130772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":145,"alternative-id":["10.3389\/fimmu.2026.1890822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1890822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1890822"}}